Fusion Inhibitory Peptide

Fusion Inhibitory Peptide (CPC catalog code FIP-001) is a synthetic coagulation cascade peptide / substrate in the coagulation category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

Published and internal research programs use Fusion Inhibitory Peptide as a reference standard in coagulation workflows — for example, chromogenic protease-activity assays and par (protease-activated receptor) signaling studies. Human clinical evidence is not established.

No. Fusion Inhibitory Peptide is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

In a coagulation workflow, Fusion Inhibitory Peptide is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Read on kinetic plate readers at 405 nm (pNA) or fluorescence (AMC / MCA) endpoints.

Lyophilized peptide stable at −20 °C. Reconstituted stocks are typically kept at 4 °C for short assays. Follow your institution's standard operating procedures for handling synthetic peptides.

This kindr reference page mirrors CPC Scientific's catalog metadata for FIP-001. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.

Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.